Imunon (LTS:0HUZ) Accounts Payable : $1.30 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Imunon Accounts Payable?

Imunon's Accounts Payable for the quarter that ended in Dec. 2024 was $1.30 Mil.

Imunon's quarterly Accounts Payable increased from Jun. 2024 ($1.97 Mil) to Sep. 2024 ($2.36 Mil) but then declined from Sep. 2024 ($2.36 Mil) to Dec. 2024 ($1.30 Mil).

Imunon's annual Accounts Payable declined from Dec. 2022 ($3.59 Mil) to Dec. 2023 ($3.52 Mil) and declined from Dec. 2023 ($3.52 Mil) to Dec. 2024 ($1.30 Mil).

Imunon Accounts Payable Historical Data

The historical data trend for Imunon's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Accounts Payable Chart

Imunon Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable

Get a 7-Day Free Trial

2.25

2.55

3.59

3.52

1.30

Imunon Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Payable	Get a 7-Day Free Trial															3.52	2.36	1.97	2.36	1.30

Imunon Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Imunon Accounts Payable Related Terms

Thank you for viewing the detailed overview of Imunon's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Imunon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (LTS:0HUZ) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

IMNN:USA CBO:Germany

Address

997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648

Website

https://www.imunon.com

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Imunon Headlines

No Headlines